Literature DB >> 20541696

Glycogen synthase kinase-3 and leukemia: restoring the balance.

Noah W Birch1, Nancy J Zeleznik-Le.   

Abstract

The role of GSK-3 in oncogenesis is paradoxical, acting as a tumor suppressor in some cancers and potentiating growth in others. In this issue of Cancer Cell, Wang et al. provide some mechanistic insight into GSK-3 activity's role in potentiating leukemias which are dependent on homeobox (HOX) gene misregulation. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Year:  2010        PMID： 20541696      PMCID： PMC2987688          DOI： 10.1016/j.ccr.2010.05.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  The renaissance of GSK3.

Authors:  P Cohen; S Frame
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

Review 2.  The glamour and gloom of glycogen synthase kinase-3.

Authors:  Richard S Jope; Gail V W Johnson
Journal:  Trends Biochem Sci       Date:  2004-02       Impact factor: 13.807

3.  Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.

Authors:  Zhong Wang; Kevin S Smith; Mark Murphy; Obdulio Piloto; Tim C P Somervaille; Michael L Cleary
Journal:  Nature       Date:  2008-09-17       Impact factor: 49.962

Review 4.  The Hox genes and their roles in oncogenesis.

Authors:  Nilay Shah; Saraswati Sukumar
Journal:  Nat Rev Cancer       Date:  2010-04-01       Impact factor: 60.716

5.  GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis.

Authors:  Zhong Wang; Masayuki Iwasaki; Francesca Ficara; Chenwei Lin; Christina Matheny; Stephen H K Wong; Kevin S Smith; Michael L Cleary
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

6.  HOX deregulation in acute myeloid leukemia.

Authors:  Kim L Rice; Jonathan D Licht
Journal:  J Clin Invest       Date:  2007-04       Impact factor: 14.808

7.  Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice.

Authors:  Jian Huang; Yi Zhang; Alexey Bersenev; W Timothy O'Brien; Wei Tong; Stephen G Emerson; Peter S Klein
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

Review 8.  Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy.

Authors:  Jia Luo
Journal:  Cancer Lett       Date:  2008-07-07       Impact factor: 8.679

Review 9.  Targeting GSK-3: a promising approach for cancer therapy?

Authors:  Andrei V Ougolkov; Daniel D Billadeau
Journal:  Future Oncol       Date:  2006-02       Impact factor: 3.404

Review 10.  Glycogen synthase kinase 3: more than a namesake.

Authors:  Geetha Vani Rayasam; Vamshi Krishna Tulasi; Reena Sodhi; Joseph Alex Davis; Abhijit Ray
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739
  10 in total
  4 in total

Review 1.  Tolerogenic dendritic cells and rheumatoid arthritis: current status and perspectives.

Authors:  Yunpeng Zhao; Aijun Zhang; Hongxia Du; Shuya Guo; Bin Ning; Shangyou Yang
Journal:  Rheumatol Int       Date:  2011-09-09       Impact factor: 2.631

2.  Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth.

Authors:  I Azoulay-Alfaguter; R Elya; L Avrahami; A Katz; H Eldar-Finkelman
Journal:  Oncogene       Date:  2014-12-15       Impact factor: 9.867

3.  Glycogen synthase kinase-3β inhibition promotes lysosome-dependent degradation of c-FLIPL in hepatocellular carcinoma.

Authors:  Na Zhang; Xiaojia Liu; Lu Liu; Zhesong Deng; Qingxuan Zeng; Weiqiang Pang; Yang Liu; Danqing Song; Hongbin Deng
Journal:  Cell Death Dis       Date:  2018-02-14       Impact factor: 8.469

Review 4.  Glycogen Synthase Kinase 3β in Cancer Biology and Treatment.

Authors:  Takahiro Domoto; Masahiro Uehara; Dilireba Bolidong; Toshinari Minamoto
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.